458075.fig.002a
(a)
458075.fig.002b
(b)
458075.fig.002c
(c)
458075.fig.002d
(d)
458075.fig.002e
(e)
458075.fig.002f
(f)
458075.fig.002g
(g)
458075.fig.002h
(h)
Figure 2: Effect of AGAF on MAPK and IκBα phosphorylation in RAW 264.7 cells. (a) AGAF treatment (100 μg/mL) for 0 to 30 min in RAW 264.7 cells. (b–e) The phosphorylation of ERK, p38, IκBα, and JNK in RAW 264.7 cells treated with AGAF (50, 100, and 150 μg/mL) or a medium for 15 min. (f) The phosphorylation of ERK in RAW 264.7 cells that were pretreated with 10 μM ERK inhibitor, PD98059, for 60 min and then treated with AGAF (50, 100, and 150 μg/mL) or a medium for 15 min. (g) The phosphorylation of p38 in RAW 264.7 cells that were pretreated with 10 μM p38 inhibitor, SB203580, for 60 min and then treated with AGAF (50, 100, and 150 μg/mL) or a medium for 15 min. (h) The phosphorylation of IκBα in RAW 264.7 cells that were pretreated with 25 μM IκBα inhibitor, PDTC, for 60 min and then treated with AGAF (50, 100, and 150 μg/mL) or a medium for 15 min. The protein expression was assessed via western blotting. The values are presented as the mean SD; . * , ** and *** as compared to control group as analyzed by Dunnett’s test.